- The share
- Press releases
- Financial calendar
- Financial reports
- Financial reports – ESEF
- Prospectus and material offerings
- Financial presentations
- Corporate governance
- Analyst Coverage
- Code of Conduct
- Environmental Policy
- Code of Conduct for Suppliers
- Contact us
- Thank you
Shares in Xvivo Perfusion AB will begin trading on NASDAQ OMX First North on October 8, 2012
Xvivo Perfusion AB was spun off from Vitrolife AB on October 1, whereby Vitrolife shareholders received one share in Xvivo Perfusion for each share in Vitrolife. Xvivo Perfusion shares have been approved for trade on NASDAQ OMX First North and the first day for trade will be October 8.
In view of the listing on First North, Xvivo Perfusion is today publishing a company description that is available on the company’s website.
October 4, 2012
Xvivo Perfusion AB (publ)
For further information, please contact:
Magnus Nilsson, CEO or Christoffer Rosenblad, CFO Xvivo Perfusion AB
Tel: +46 31 788 21 50 (switchboard) or +46 31 788 21 59 (Christoffer direct)
The information was submitted for publication on October 4, 2012 at 8:30 a.m.
This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.